ポスター：スクリーニングからシーケンシングまで – 抗体創薬を支えるGenedataのデジタル基盤

February 18, 2026

抗体創薬では、ターゲット探索～スクリーニング～開発適性評価にいたるまで、膨大かつ複雑なデータが生成されるため、初期段階からデータを統合する環境が求められています。Genedata Biopharma Platformは、装置・アッセイ・解析パイプラインの情報を統合してデータの一元管理とトレーサビリティを確保し、NGSワークフローの自動化やAI利活用により、有望な候補の早期特定と迅速な意思決定をサポートします。

Antibody discovery programs generate vast amounts of complex data across workflows, from target exploration and immunization to library generation, screening, and developability assessment. To fully leverage this information, teams need a sample‑centric, connected environment that unifies biophysical, functional, and next‑generation sequencing (NGS) data from the start. The Genedata Biopharma Platform serves as this central hub by harmonizing inputs from instruments, assays, and analysis pipelines into a single source of truth. This creates an environment where sequences, samples, and results remain linked throughout the process, ensuring complete end‑to‑end traceability. Researchers can monitor how sequence variants appear, follow screening outcomes as they progress, and review relevant metadata in real time. Integrated NGS-based workflows automate sequence processing, repertoire analytics, and early liability identification across various sequencing technologies. By connecting all evidence streams at the sample level, the platform supports earlier identification of promising targets and therapeutic candidates, reduces attrition, and strengthens collaboration between discovery, engineering, and downstream development teams. This unified, structured data foundation not only accelerates innovation and de‑risking in early discovery but also prepares organizations for advanced analytics and AI‑driven insights.